WASHINGTON, DC (October 10, 2017) — LUNGevity Foundation, the nation’s leading lung cancer-focused organization, today announced that Marc Swerdlow has been elected Vice-Chairman and Treasurer of the Board of Directors. Mr. Swerdlow, Principal and Chief Operating Officer at Magellan Investment Partners LLC, has served as a valuable member of LUNGevity’s Board since 2004. The Board is composed of global leaders who lend their expertise, knowledge, and passion to further LUNGevity’s work of changing outcomes for people with lung cancer through research, education and support, and vital public policy work.
“Marc’s new position is the culmination of 13 years of meaningful service to the organization,” said Andrea Ferris, President and CEO of LUNGevity Foundation. “We know how personal our vision is to him, and we are grateful for the leadership and financial acumen he brings to the Board at such a pivotal time, as we broaden our reach to better serve the lung cancer community.”
“Having lost both of my parents to lung cancer, I feel a strong connection to families that are dealing with the diagnosis today,” said Swerdlow. “I’m honored to step into the role held by Jerry Sorkin, a close friend who lost his battle with lung cancer in 2016. Over the twelve years of being on Lungevity’s Board we’ve seen a tremendous advancement in research, and as a result have been able to increase the quality of people’s lives. We can positively look to the future where we accomplish our vision of creating a world where no one dies of lung cancer.”
Marc has served as Principal at Magellan Investment Partners LLC and Chief Operating Officer since 2014. MIP is the investment affiliate of Magellan Development Group focusing on the acquisition of core plus and value add multi-family properties in key strategic markets.
Marc has been involved in commercial real estate investments since 1986. He was the President and General Counsel at Waterton Associates LLC and Waterton Commercial Properties, LLC, and a Senior Investment Manager with GE Capital Real Estate. Before joining GE Capital, Mr. Swerdlow was a Senior Vice President with Heitman Advisory Corporation.
Mr. Swerdlow graduated from the University of Iowa with a bachelor’s degree in finance and holds a JD degree from DePaul University. Marc is president of Har Shalom Congregation in Highland Park.
About LUNGevity Foundation
LUNGevity is the nation's leading lung cancer organization investing in lifesaving, translational research and providing support services and education for patients and caregivers. LUNGevity’s goals are three-fold: (1) accelerate research to patients, (2) empower patients to be active participants in their treatment decisions, and (3) remove barriers that patients face in accessing the right treatments.
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. LUNGevity’s comprehensive resources include a medically vetted website, a toll-free HELPLine in partnership with CancerCare®, a unique Lung Cancer Navigator app, peer-to-peer mentoring for patients and caregivers (LUNGevity LifeLine), and survivorship conferences. LUNGevity also helps patients find and navigate clinical trials through our Clinical Trial Finder tool, a Clinical Trial Ambassador program, and participation with EmergingMed.
Our vision is a world where no one dies of lung cancer. For more information about LUNGevity Foundation, please visit www.LUNGevity.org.
About Lung Cancer in the U.S.
- About 1 in 16 Americans will be diagnosed with lung cancer in their lifetime
- More than 222,000 people in the U.S. will be diagnosed with lung cancer this year
- About 60%-65% of all new lung cancer diagnoses are among people who have never smoked or are former smokers
- Lung cancer takes more lives than the next three leading cancers (colorectal, breast, and prostate) combined
- Only 18% of all people diagnosed with lung cancer will survive 5 years or more, BUT if it’s caught before it spreads, the chance of 5-year survival improves dramatically